The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shapiro, V. S.
Right arrow Articles by Weiss, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shapiro, V. S.
Right arrow Articles by Weiss, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
The Journal of Immunology, 1998, 161: 6455-6458.
Copyright © 1998 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: Nuclear Factor of Activated T Cells and AP-1 Are Insufficient for IL-2 Promoter Activation: Requirement for CD28 Up-Regulation of RE/AP1

Virginia Smith Shapiro*, Marianne Newton Mollenauer{dagger} and Arthur Weiss2,*,{dagger}

* Department of Medicine and {dagger} Howard Hughes Medical Institute, University of California, San Francisco, CA 94143

IL-2 gene transcription in T cells requires both TCR and costimulatory signals. IL-2 promoter activation in Jurkat T cells stimulated with superantigen presented by Raji B cells requires CD28 activation. The addition of rCTLA4Ig, which blocks CD28 binding to its ligand, to the cultures decreased IL-2 promoter activation by >80%. Interestingly, CTLA4Ig did not significantly inhibit the activation of either NF of activated T cells (NFAT) or AP-1 reporters. Therefore, activation of NFAT and AP-1 is insufficient for IL-2 promoter activation. In contrast, an RE/AP reporter was blocked by CTLA4Ig by >90%. Thus, the requirement for CD28 in IL-2 promoter activation appears to be due to RE/AP and not the NFAT or AP-1 sites. In addition, these data suggest that transcriptional activation of RE/AP is not mediated by NFAT, because activation of a NFAT reporter is not affected by the addition of CTLA4Ig.




This article has been cited by other articles:


Home page
Int ImmunolHome page
B. Li, A. Samanta, X. Song, K. T. Iacono, P. Brennan, T. A. Chatila, G. Roncador, A. H. Banham, J. L. Riley, Q. Wang, et al.
FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease
Int. Immunol., July 1, 2007; 19(7): 825 - 835.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Legarda-Addison and A. T. Ting
Negative Regulation of TCR Signaling by NF-{kappa}B2/p100
J. Immunol., June 15, 2007; 178(12): 7767 - 7778.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Li, A. Samanta, X. Song, K. T. Iacono, K. Bembas, R. Tao, S. Basu, J. L. Riley, W. W. Hancock, Y. Shen, et al.
FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression
PNAS, March 13, 2007; 104(11): 4571 - 4576.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. B. Cismasiu, S. Ghanta, J. Duque, D. I. Albu, H.-M. Chen, R. Kasturi, and D. Avram
BCL11B participates in the activation of IL2 gene expression in CD4+ T lymphocytes
Blood, October 15, 2006; 108(8): 2695 - 2702.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. E. Perchonock, M. C. Fernando, W. J. Quinn III, C. T. Nguyen, J. Sun, M. J. Shapiro, and V. S. Shapiro
Negative Regulation of Interleukin-2 and p38 Mitogen-Activated Protein Kinase during T-Cell Activation by the Adaptor ALX.
Mol. Cell. Biol., August 1, 2006; 26(16): 6005 - 6015.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Xing, L. T. Donlin, R. H. Miller, and K. Alexandropoulos
The Adapter Molecule Sin Regulates T-Cell-Receptor-Mediated Signal Transduction by Modulating Signaling Substrate Availability
Mol. Cell. Biol., May 15, 2004; 24(10): 4581 - 4592.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. A. Schubert, R. Q. Cron, A. M. Cleary, M. Brunner, A. Song, L.-S. Lu, P. Jullien, A. M. Krensky, and D. B. Lewis
A T Cell-specific Enhancer of the Human CD40 Ligand Gene
J. Biol. Chem., February 22, 2002; 277(9): 7386 - 7395.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. S. Shapiro, M. N. Mollenauer, and A. Weiss
Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression
Blood, July 1, 2001; 98(1): 187 - 193.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Gonzalez, C. Punzon, M. Gonzalez, and M. Fresno
HIV-1 Tat Inhibits IL-2 Gene Transcription Through Qualitative and Quantitative Alterations of the Cooperative Rel/AP1 Complex Bound to the CD28RE/AP1 Composite Element of the IL-2 Promoter
J. Immunol., April 1, 2001; 166(7): 4560 - 4569.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Michel, G. Mangino, G. Attal-Bonnefoy, L. Tuosto, A. Alcover, A. Roumier, D. Olive, and O. Acuto
CD28 Utilizes Vav-1 to Enhance TCR-Proximal Signaling and NF-AT Activation
J. Immunol., October 1, 2000; 165(7): 3820 - 3829.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
L. H. Glimcher and K. M. Murphy
Lineage commitment in the immune system: the T helper lymphocyte grows up
Genes & Dev., July 15, 2000; 14(14): 1693 - 1711.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.